Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets
出版年份 2021 全文链接
标题
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets
作者
关键词
-
出版物
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 40, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-05-18
DOI
10.1186/s13046-021-01968-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC
- (2021) Kaixin Du et al. MOLECULAR THERAPY
- Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells
- (2021) Simon J Dovedi et al. Cancer Discovery
- The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
- (2021) Juanjuan Yuan et al. Protein & Cell
- Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2020) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
- (2020) Shukui Qin et al. LANCET ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Icaritin‐induced immunomodulatory efficacy in advanced hepatitis B virus‐related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival
- (2020) Shu‐Kui Qin et al. CANCER SCIENCE
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Icaritin inhibits PD‐L1 Expression by Targeting Protein IκB Kinase α
- (2020) Dongliang Mo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma
- (2020) Chun A. Changou et al. ONCOLOGIST
- Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
- (2019) Ying Jiang et al. NATURE
- Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
- (2019) Shuang Qin et al. Journal of Hematology & Oncology
- Toripalimab: First Global Approval
- (2019) Susan J. Keam DRUGS
- First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers
- (2019) Ying Fan et al. BMC CANCER
- Lenvatinib: A Review in Hepatocellular Carcinoma
- (2019) Zaina T. Al-Salama et al. DRUGS
- Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor Galunisertib ( LY 2157299) in Advanced Hepatocellular Carcinoma
- (2019) Sandrine Faivre et al. LIVER INTERNATIONAL
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- p38γ is essential for cell cycle progression and liver tumorigenesis
- (2019) Antonia Tomás-Loba et al. NATURE
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Targeting mTOR for cancer therapy
- (2019) Hui Hua et al. Journal of Hematology & Oncology
- A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- (2019) R.K. Kelley et al. Clinical and Translational Gastroenterology
- Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
- (2019) Shengnan Yu et al. Molecular Cancer
- 678PDOutcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
- (2019) L Rimassa et al. ANNALS OF ONCOLOGY
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
- (2019) Qiang Gao et al. CELL
- Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
- (2019) Qiming Zhang et al. CELL
- Emerging agents and regimens for hepatocellular carcinoma
- (2019) Xiao-Dong Zhu et al. Journal of Hematology & Oncology
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
- (2018) Tong Zhang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- MAGE-A antigens as targets for cancer immunotherapy
- (2018) Erik Schooten et al. CANCER TREATMENT REVIEWS
- Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond
- (2018) Jean-Luc Raoul et al. CANCER TREATMENT REVIEWS
- Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
- (2018) Alicia J. Angelbello et al. CHEMICAL REVIEWS
- Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
- (2018) Xiaolei Li et al. Journal of Hematology & Oncology
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
- (2018) Lorenza Rimassa et al. LANCET ONCOLOGY
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications
- (2018) Chun-Ming Wong et al. Nature Reviews Gastroenterology & Hepatology
- Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations
- (2018) Jesse J. Salk et al. NATURE REVIEWS GENETICS
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Future of Precision Medicine: Potential Impacts for Health Technology Assessment
- (2018) James Love-Koh et al. PHARMACOECONOMICS
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China.
- (2018) Zhihong Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS001, an anti-PD-1 monoclonal antibody.
- (2018) Xinan Sheng et al. JOURNAL OF CLINICAL ONCOLOGY
- REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
- (2018) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- The hepatocellular carcinoma market
- (2018) Joshua Dawkins et al. NATURE REVIEWS DRUG DISCOVERY
- Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
- (2018) Takayuki Kimura et al. CANCER SCIENCE
- NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
- (2018) Nadine van Montfoort et al. CELL
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
- (2018) Pascale André et al. CELL
- NKG2A, a New Kid on the Immune Checkpoint Block
- (2018) John B. Haanen et al. CELL
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Targeted and Immune-Based Therapies for Hepatocellular Carcinoma
- (2018) Tim F. Greten et al. GASTROENTEROLOGY
- Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects
- (2018) Xiaoyun Lu et al. JOURNAL OF MEDICINAL CHEMISTRY
- PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer.
- (2018) Vito W Rebecca et al. Cancer Discovery
- Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
- (2018) Xingliang Guo et al. Frontiers in Pharmacology
- Oncolytic virus immunotherapy: future prospects for oncology
- (2018) Junaid Raja et al. Journal for ImmunoTherapy of Cancer
- Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1
- (2017) Hui Li et al. HEPATOLOGY
- TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
- (2017) William C. Dougall et al. IMMUNOLOGICAL REVIEWS
- Chemotherapy for hepatocellular carcinoma: current status and future perspectives
- (2017) Masafumi Ikeda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Recent advances of bispecific antibodies in solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- Chimeric antigen receptor T cells: a novel therapy for solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice
- (2017) Shanshan Zhang et al. JOURNAL OF HEPATOLOGY
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Recombinant humanised anti-PD-1 monoclonal antibody (JS001) treatment for patients with refractory or metastatic nasopharyngeal carcinoma: preliminary results of an open-label, phase 1b/2, clinical study
- (2017) Ruihua Xu et al. LANCET ONCOLOGY
- Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment
- (2017) Fubo Zhou et al. MEDICINAL RESEARCH REVIEWS
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- Nivolumab Approved for Liver Cancer
- (2017) Cancer Discovery
- Artemisinin-A Gift from Traditional Chinese Medicine to the World (Nobel Lecture)
- (2016) Youyou Tu ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Oncolytic virus therapy: A new era of cancer treatment at dawn
- (2016) Hiroshi Fukuhara et al. CANCER SCIENCE
- Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
- (2016) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy
- (2016) C. S. Hinrichs CLINICAL CANCER RESEARCH
- PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
- (2016) Jiqing Sai et al. CLINICAL CANCER RESEARCH
- Epigenetics in liver disease: from biology to therapeutics
- (2016) Timothy Hardy et al. GUT
- Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
- (2016) Patricia Mucci LoRusso JOURNAL OF CLINICAL ONCOLOGY
- Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma
- (2016) A. R. Singh et al. MOLECULAR CANCER THERAPEUTICS
- TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells
- (2016) Nathan Ungerleider et al. MOLECULAR CARCINOGENESIS
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
- (2016) Lorenza Rimassa et al. Oncotarget
- Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival
- (2016) Omar Abdel-Rahman et al. Expert Review of Gastroenterology & Hepatology
- Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA
- (2016) Fengqian Chen et al. Biomaterials Science
- Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
- (2016) Lucie Heinzerling et al. Journal for ImmunoTherapy of Cancer
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma
- (2015) Augusto Villanueva et al. HEPATOLOGY
- CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice
- (2015) Yunching Chen et al. HEPATOLOGY
- Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma
- (2015) ZhengGang Ren et al. JOURNAL OF CLINICAL ONCOLOGY
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
- (2015) Kornelius Schulze et al. NATURE GENETICS
- Advances in targeted therapies for hepatocellular carcinoma in the genomic era
- (2015) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- T cell exclusion, immune privilege, and the tumor microenvironment
- (2015) J. A. Joyce et al. SCIENCE
- First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
- (2015) M. Hagel et al. Cancer Discovery
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway
- (2015) Hong Zhao et al. Oncotarget
- Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients
- (2015) Maria Serova et al. Oncotarget
- PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment
- (2015) Wing Lam et al. Scientific Reports
- Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
- (2014) H. Gao et al. CLINICAL CANCER RESEARCH
- Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
- (2014) Q. Xiang et al. CLINICAL CANCER RESEARCH
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Alterations of the human gut microbiome in liver cirrhosis
- (2014) Nan Qin et al. NATURE
- Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer
- (2013) Xiaoqiang Tang CANCER LETTERS
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Reassessing target antigens for adoptive T-cell therapy
- (2013) Christian S Hinrichs et al. NATURE BIOTECHNOLOGY
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
- (2013) Jeong Heo et al. NATURE MEDICINE
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma
- (2012) Seiki Miura et al. BMC CANCER
- Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
- (2012) Douglas Hanahan et al. CANCER CELL
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
- (2012) D. Mahadevan et al. EUROPEAN JOURNAL OF CANCER
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- Targeted Therapies for Hepatocellular Carcinoma
- (2011) Augusto Villanueva et al. GASTROENTEROLOGY
- Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
- (2011) Antonio Di Stasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treating cancer with genetically engineered T cells
- (2011) Tristen S. Park et al. TRENDS IN BIOTECHNOLOGY
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity
- (2008) J. R. Garlich et al. CANCER RESEARCH
- Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention
- (2008) Han Kiat Ho et al. JOURNAL OF HEPATOLOGY
- Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
- (2008) Byeong-Ho Park et al. LANCET ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now